We would love to hear your thoughts about our site and services, please take our survey here.
Stifle and Investec are brokers. They buy and sell our shares when we ask them to buy and sell. Their trades are irrelevant.
It won't be suspended until the bidding process ends. It will take 3 months from the time the company announces offers. Bids can keep coming in throughout the process.
The consultation process ends on Friday. We'll get their recommendations after that. That's why all these iis have bought in substantially. We might get a bit of a bidding scrum from big pharma. The main suppliers for chronic kidney disease drugs at the moment are AstraZeneca and Thermo Fischer. Not to say that others might not want to take this test. It's worth billions potentially in it's own right. 10 million Americans have diabetes 2. Around 89 million people worldwide also have it. At $950.00 a test it's a valuable product. I think it will go for £2.00.
*agree to disagree. Damn spellchecker!
They'll get sales when they get nationwide US insurance coverage. I've been in shares before that spike to over £1.5 because they have a breakthrough test but then plummets because they aren't in the system and therefore they don't get sales. This is very obvious. When I have sold and pointed this out I have been much criticised 😄
This is going to be as embedded in the commissioning environment as it can be, once the insurance industry confirms the results of the consultation. Next couple of months is my guess. You can't sell if you haven't been properly signed off. But yeah, demand is massive. We can agree to disease then hey.
Jatw, have you done any reading at all on this stock? It got FDA approval last June.
My expectation is £2.00 for a buy out before the end of the year. They have £12 million now. The test will be worth billions over 5 years. If either AstraZeneca or Thermo Fischer take it they will extend sales of their drug treatments- already making TF $5billion a year. The insurance industry has a vested interest in getting these tests widely adopted by the at risk group. 10 million US citizens with diabetes 2 or chronic kidney disease at early stage. The earlier people are diagnosed the easier it is to prevent acute kidney disease. Acute kidney disease is a killer. Dialysis and kidney replacement costs $35 billion.
Everyone wins if this test is widely adopted. The US tax payer, the US medical insurance industry, the pharma companies and those millions of at risk patients get a life saver. The US economy wins too. People can stay in productive work for longer. Win, win, win,win and finally win. I suppose us pis finally also win.
I did say in an earlier post with this title that we could see something to coincide with international kidney day. This makes the US national insurance coverage even more nailed on. I'm sticking my neck out for a definite now.
It was due at the end of March. It's always close to the wire. That's 2 weeks away. For the sp to build up again nicely. Which it most certainly will.
If it's any comfort Harwood now have 12% of RENX and their average is much higher than this. Christopher Mills is a bit of a star trader in small caps. Had a few ten baggers hey? Who knows best? Christopher Mills, CEO at Harwood and on RENX's board or Tom, Dick and Harry shorters?
For nationwide health insurance coverage. Then a few weeks potentially for a decision. I think we'll find out who the bidder is as soon as we get the recommendation. Think that's a dead cert. The US government has bought in for all it's services personnel and the US veterans have set up their systems already to link Medicare to the RENX test for their members. The regulatory authority has described the test as necessary for those with diabetes 2 and part of the treatment plan for chronic kidney disease.
These shorters are just taking advantage of the time The Morning Star covered this well on 9th February. Easy enough to dyor these days hey. Holding.
Hebridian, are you in? Why are you here otherwise?
Looks very much like UKEF are in because the Times leaked that the deal has been agreed by government.
Reckon we'll find out soon. Can't wait to see the back of Riverfort.
The 3rd license is due this month so goodness knows why anyone would sell now. As soon as it's confirmed we'll go up 35% and keep going up until the whole deal is completed formally. Imho. Because I have seen it all before.
Mms do this all the time. It's Aim. Surprised they have any investors left. Certainly we're a diminished body. If you sell cheap, they'll take your shares and sell them for 3 times the price when the next license arrives and the due process with Ping and Shell is announced for all 3 licences.
Not too shabby hey? Oversubscribed and a nice $12 million in the bank to take them through to takeover. International kidney day on Thursday. Hoping to see a bit of coverage.
Just checked Nasdaq. It's up to the equivalent of 35p. Which is why we're up. Happens every day. Big volume. Aim is embarrassing.
Correcting an earlier post of mine. Unicorn took 1.1% on 4th March after the takeover announcement. Pentwater took 4%. The latter have specialist teams for health and AI. Hmm. Total coincidence?
Apologies for my earlier mistake.
Hawker, yeah the shorters seem to be implying that Christopher Mills involvement and Harwood's involvement is no biggie. Harwood were small cap investment fund of the year in 2023, taking 1st, 2nd and 3rd place. They specialise in M&A and helping small companies to realise their potential. Mills has had several 10 baggers in his portfolio. This will be a 7-8 bagger from here, assuming the consultation goes well. The problem with looking at the sp day to day is that it's stressful and people sell causing volatility. This is only going one way - give it time. Shorters are making some ridiculous and nonsensical comparisons.
The US insurance industry finishes it's consultation next week. Recommendations to follow thereafter. The price is set at $950.00 a test. 10 million people in the US have diabetes 2, predicted to rise. If nothing is done kidney disease will become the 4th biggest cause of death in the US. Something will be done. There's a Democrat in the top job. Thank goodness.
I think SB's theory that this is going to iis is likely. Harwood et al will probably take the lot. They're hardly 'bucket shop'. They are all well connected. I expect they know who the bidder is and they definitely know what the business case is because it's all in the public domain. US insurance coverage for all citizens who may have or may at some point get type 2 diabetes or chronic kidney disease. It's in the insurance industry interest to get better engagement with this group because they spend 7 times as much on acute kidney disease and dialysis than they do on treatment for chronic kidney disease. Reckon Thermo Fischer and Astra Zeneca will end up fighting it out for the takeover whoever's bid atm. Worth another $5 billion just on additional drug treatment - once early detection is achieved they can prevent acute disease forming but they can't reverse it.
This stock has gone up 170% in less than a month. Of course the shorters are getting excited. The US pushed it up 650% at one point. We all know they need cash. Maj the self appointed guru said this would be 10p for the placing. He pretends he's connected. Now he says 18-20p. Changed his mind already. Shorts are mostly closing. Institutional investors are buying in. Unicorn just took 4%.
I'm not fascinated by what the shorts are doing. I am interested in the business case for this product. It's very good. As I have discussed. Maj doesn't engage with the business case. He focuses on the volatility in the sp to scare people into selling. It can go up just as fast as it can go down. There still aren't that many shares in issue considering the potential for a decent price at takeover.
I think the bidder may have put a caveat on the offer- ie. subject to the insurance industry in the US recommending the test. That would be sensible wouldn't it? They will disclose when the outcome of the consultation is announced imho.